Clinical Trial Update: Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies [NA]

View source ↗

Summary

Clinical trial update regarding Chimeric Antigen Receptor T Cells (CART) therapy for refractory/relapsed B-cell hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• Chimeric Antigen Receptor T Cells (CART) Therapy

Snippet

Sponsor: Innovative Cellular Therapeutics Co., Ltd. | Conditions: Leukemia, B-Cell, Lymphoma, B-Cell | NA | Status: UNKNOWN